CROWN, John et al. TCHL – a phase II neo-adjuvant study assessing TCH (docetaxel, carboplatin and trastuzumab) and TCHL (docetaxel, carboplatin, trastuzumab and lapatinib) in HER-2 positive breast cancer patients: a 5-year follow-up with serum biomarker analysis. Acta Oncologica, [S. l.], v. 64, p. 751–760, 2025. DOI: 10.2340/1651-226X.2025.43143. Disponível em: https://medicaljournalssweden.se/actaoncologica/article/view/43143. Acesso em: 27 may. 2026.